QI
CBIO

QS Investors’s Crescent Biopharma CBIO Stock Holding History

QS Investors’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		$373K Buy
1,607
+592
+58% +$151K ﹤0.01% 852
2021
Q1 		$306K Buy
+1,015
New +$364K ﹤0.01% 981

Other funds holding CBIO

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

QS Investors's CBIO Position: Q2 2021 in Review

QS Investors increased its Crescent Biopharma (CBIO) stake by 58% in Q2 2021, buying an estimated $151K and bringing the position to 1,607 shares worth $373K. The position accounts for ﹤0.01% of the portfolio, ranked #852.

QS Investors first reported a position in CBIO in Q1 2021 and has held it in 2 quarters since. 58 funds tracked by Wall St. Rank hold CBIO as of Q2 2021.

  • QS Investors held 1,607 shares of Crescent Biopharma worth $373K as of Q2 2021.
  • QS Investors bought 592 Crescent Biopharma shares in Q2 2021, an estimated $151K.
  • Crescent Biopharma made up ﹤0.01% of QS Investors's portfolio in Q2 2021, its #852 holding.
  • QS Investors first reported a position in Crescent Biopharma in Q1 2021 and has held it in 2 quarters since.
  • 58 funds tracked by Wall St. Rank held Crescent Biopharma as of Q2 2021.

Based on QS Investors's 13F filing for Q2 2021, filed 13 Aug 2021.